Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is a leading biotechnology company that develops protein-based drugs used to battle a variety of diseases and conditions, including cancer, high cholesterol, inflammatory ailments, cardiovascular and metabolic diseases, infectious disease, rare diseases, and eye diseases. Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. In 1988, Regeneron was founded by Leonard S. Schleifer, MD, PhD, a young neurologist and assistant professor at Cornell University Medical College.

Pharmaceutical and Medicine Manufacturing; Chemical Manufacturing; Manufacturing

Pharmaceutical Preparations; Chemicals and Allied Products; Manufacturing

$13120M